Nick Giannoukakis
9Patents
3h-index
10Co-inventors
50Inventor score
Filing activity: Apr 27, 2001 → Mar 8, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6936468B2 | Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same | Chemistry; Metallurgy | 8 | Expired |
| US7964574B2 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes | Chemistry; Metallurgy | 4 | Active |
| US8022046B2 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes | Chemistry; Metallurgy | 3 | Active |
| US8389493B2 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes | Chemistry; Metallurgy | 3 | Active |
| US9724365B2 | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies | Chemistry; Metallurgy | 1 | Active |
| US10272112B2 | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies | Chemistry; Metallurgy | 1 | Active |
| US10940164B2 | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies | Chemistry; Metallurgy | 0 | Active |
| US10105334B2 | Particle formulations of all-trans retinoic acid and transforming growth factor beta for the treatment of type 1 diabetes mellitus | Human Necessities | 0 | Active |
| US9115357B2 | Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.